Pancreatic Cancer

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, define NRG1 fusions and outline their incidence and effect on prognosis.

Developers plan to assess onvansertib plus standard of care as a frontline treatment for patients with metastatic pancreatic ductal adenocarcinoma in an investigator-initiated trial.

LSAM-PTX plus standard of care appears efficacious in a small population of patients with locally advanced pancreatic cancer.

Clearance of an automated immunoassay allows practices to measure chromogranin A concentration in human serum, thereby tracking disease progression in those with gastroenteropancreatic neuroendocrine tumors.

The safety profile of cabozantinib as a treatment for patients with advanced pancreatic neuroendocrine tumors in the phase 3 CABINET trial is comparable with previous reports of the agent.

The investigational drug MAb-AR20.5 is the first monoclonal antibody targeting MUC1 to receive orphan drug designation from the FDA as a treatment for pancreatic cancer.

Elraglusib is currently under evaluation as a treatment for patients with several types of advanced cancers as part of the phase 1/2 1801 trial.

Data from the phase 1/2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive cancer support the FDA’s breakthrough therapy designation for the agent as a treatment for pancreatic cancer.

The oncolytic adenovirus VCN-01 is under investigation as a treatment for metastatic pancreatic ductal adenocarcinoma in the phase 2b VIRAGE trial.

Investigators expect to have a readout of topline data from the phase 2 OPTIMIZE-1 trial evaluating mitazalimab plus chemotherapy in metastatic pancreatic ductal adenocarcinoma in early 2024.

The FDA sets a Prescription Drug User Fee Act date of February 13, 2024 for NALIRIFOX as a treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Findings from the phase 3 NAPOLI 3 trial support NALIRIFOX as a novel reference regimen for first-line metastatic pancreatic ductal adenocarcinoma.

Medicaid expansion may help overcome inequities in access to care for pancreatic and gastric cancers, with notable benefit in Black patients, according to an expert from The University of Texas MD Anderson Cancer Center.

A positive R0 resection rate helped to confirm the noninferiority of minimally invasive distal pancreatectomy compared with open distal pancreatectomy in those with resectable pancreatic cancer.

Claudin 18.2–targeting antibody-drug conjugate ATG-022 is under assessment as part of the phase 1 CLINCH study in patients with advanced or metastatic solid malignancies.

Mitazalimab is currently under investigation in combination with chemotherapy as a treatment for patients with metastatic pancreatic ductal adenocarcinoma in the phase 2 OPTIMIZE-1 trial.

PYX-201 is currently being investigated in a phase 1 trial in patients with solid tumors.

Data from a Chinese phase 1/2 trial suggest that osemitamab monotherapy may yield prolonged responses in Claudin18.2-expressing pancreatic cancer.

A first-in-human phase 1/2a trial will assess anti-PAUF monoclonal antibody PBP1510 in advanced/metastatic pancreatic cancer.

Data from the phase 3 TIGeR-PaC trial indicates that patients with locally advanced pancreatic cancer experienced notable survival benefit with RenovoGem vs chemotherapy.

An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.

Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.

An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.

Results from the phase 1/2 CodeBreaK 100 trial indicate that sotorasib yields positive anticancer activity and safety in patients with pancreatic cancer harboring KRAS p.G12C mutations.

Adjuvant chemotherapy following multiagent neoadjuvant chemotherapy and surgical resection produced better overall survival among patients with pancreatic ductal adenocarcinoma vs those who did not receive adjuvant treatment.

Investigators report evidence of early efficacy with SEA-CD40, chemotherapy, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

A combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline yields a statistically significant survival benefit compared with nab-paclitaxel and gemcitabine in a population diagnosed with metastatic pancreatic ductal adenocarcinoma.

The FDA grants orphan drug designation to investigational G-quadruplex transcription inhibitor QN-302 for pancreatic cancer.

Among patients with metastatic pancreatic ductal adenocarcinoma, mitazalimab plus chemotherapy yielded a positive objective response rate in the phase 2 OPTIMIZE-1 trial.

Data from the phase 1/2 CodeBreaK 100 trial indicated that 84% of patients with KRAS G12C-mutated pancreatic cancer treated with sotorasib experienced disease control.